Board President, Dr Denise Jarratt, has announced that Mr Steven Drew has been appointed as the new CEO of Hepatitis NSW, commencing on 1 October 2019.
Steven has held a number of senior appointments throughout his career. These include ten years as CEO of the Pharmaceutical Society of NSW and of the Pharmaceutical Society of Australia Limited (NSW Branch), working in the NSW Attorney’s General Department as Director of Crime Prevention, working with cabinet ministers and as a non-executive director on a number of Boards.
Dr Jarratt advised that Steven brings exceptionally strong skills and capacity in the areas of leadership, management, networking, partnership, engaging political engagement, advocacy, communication, strategic management and strategy development.
Steven will be working with outgoing CEO Stuart Loveday during a short handover period. Stuart has confirmed he will formally retire from Hepatitis NSW on 29 October 2019.
Stuart leaves with our heartfelt thanks and appreciation for 25 years of incredible service to Hepatitis NSW and to the communities of people affected by hepatitis C and hepatitis B in NSW.